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Kelly Hardes, Charlotte Summers, Martin O. Shields, William Powley, Robert Wilson,
Aili L. Lazaar, Andrew Fowler and Gavin D. PerkinsBACKGROUND Tumour necrosis factor receptor 1 (TNFR1)
signalling mediates the cell death and inflammatory effects of
TNF-a.
OBJECTIVE The current clinical trial investigated the effects
of a nebulised TNFR1 antagonist (GSK2862277) on signs
of lung injury in patients undergoing oesophagectomy.
DESIGN Randomised double-blind (sponsor unblind), pla-
cebo-controlled, parallel group study.
SETTING Eight secondary care centres, the United Kingdom
between April 2015 and June 2017.
PATIENTS Thirty-three patients undergoing elective trans-
thoracic oesophagectomy.
INTERVENTIONS Patients randomly received a single neb-
ulised dose (26 mg) of GSK2862277 (n¼17) or placebo
(n¼16), given 1 to 5 h before surgery; 14 and 16, respec-
tively competed the study.
MAIN OUTCOME MEASUREMENTS Physiological and
biochemical markers of lung injury, pharmacokinetic and
safety endpoints were measured. The primary endpoint
was the change from baseline in pulmonary vascular perme-
ability index (PVPI) at completion of surgery, measured using
single-indicator transpulmonary thermodilution. Adjusted
point estimates and 95% credible intervals (analogous to
conventional confidence intervals) were constructed for
each treatment using Bayesian statistical models.ok University Hospital, South Tees Hospitals NHS Foundation Tru
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from baseline in PVPI on completion of surgery was 0.00
(0.23, 0.39) in the placebo and 0.00 (0.24, 0.37) in the
GSK2862277 treatment groups. There were no significant
treatment-related differences in PaO2/FiO2 or Sequential
Organ Failure Assessment score. Levels of free soluble
TNFR1, Macrophage Inflammatory Protein-1 alpha and total
protein were significantly reduced in the bronchoalveolar
lavage fluid of patients treated with GSK2862277 (posterior
probability of decrease with GSK2862277 vs. placebo:
0.977; equivalent to P<0.05). The frequency of adverse
events and serious adverse events were distributed evenly
across the two treatment arms.
CONCLUSION Pre-operative treatment with a single 26 mg
inhaled dose of GSK2862277 did not result in significantly
lower postoperative alveolar capillary leak or extra vascular
lung water. Unexpectedly small increases in transpulmonary
thermodilution-measured PVPI and extra vascular lung water
index at completion of surgery suggest less postoperative
lung injury than historically reported, which may have also
compromised a clear assessment of efficacy in this trial.
GSK2862277 was well tolerated, resulted in expected lung
exposure and reduced biomarkers of lung permeability and
inflammation.
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Pilot study of a nebulised anti-tumour necrosis factor receptor-1 antibody 1015Background
Acute respiratory distress syndrome (ARDS) is broadly
characterised by rapid-onset, diffuse lung inflammation
resulting in hypoxaemia.1 Postoperative pulmonary com-
plications (PPCs), including ARDS, are common in
patients undergoing transthoracic oesophagectomy2 in
which signs of inflammation and lung injury over the
postoperative period have also been reported.3 Most
patients having oesophagectomy receive one-lung venti-
lation (OLV) for a significant part of the operative pro-
cedure, while the contralateral lung is collapsed to allow
surgical access. This technique is associated with
increased risk of developing postoperative lung injury
and PPCs, possibly due to underlying increases in pul-
monary vascular permeability, inflammation and neutro-
phil infiltration.3,4 The high rate of pulmonary
complications in patients undergoing oesophagectomy,
in addition to the more homogeneous cause and con-
trolled timing of injury, indicates oesophagectomy as a
useful ‘model’ population for the early evaluation of new
treatments for the prevention of PPCs, and ARDS, prior
to initiating larger trials in more heterogenous cohorts of
patients.5
Evidence from clinical trials with anti-TNF-a antibody
therapy in critical illness is contradictory, perhaps
because of the diverse range of different therapeutic
modalities tested (e.g. short-acting and long-acting, par-
tially selective and pan-TNF-a signalling inhibitors), and
variability in trial patient populations (e.g. biologically
enriched vs. clinically defined).6 Although patient enrich-
ment strategies are likely to be important when investi-
gating the efficacy of targeted therapies within
heterogeneous cohorts of critically ill patients, in the case
of anti-TNF-a therapies, differences in mechanism of
action may also have contributed to differences in trial
outcomes. The pleiotropic effects of TNF-a diverge at
the level of its two cellular receptors, TNF receptor 1
(TNFR1) and TNF receptor 2 (TNFR2), with studies
confirming the role of TNFR1 in promoting cell death7,8
and inflammation,9 together with an opposing role for
TNFR2 in regulating inflammation10 and promoting
resolution of injury.11 Correspondingly, TNFR1-defi-
cient mice are protected from lung injury, sepsis and
other acute organ injuries, whereas TNFR2-deficient
mice are consistently more susceptible to injury in these
models.12–16 Such data offer a potential mechanism for
why some long-acting pan-TNF inhibitors could be
harmful in acute illness, and suggest that selectively
antagonising TNFR1, while sparing TNFR2 signalling,
could be therapeutically advantageous.
GSK2862277 is a fully human domain antibody (dAb)
fragment that is a potent and selective inhibitor of TNFR1
signalling.17 Short-acting selective TNFR1 dAb inhibitors
reduce pulmonary inflammation in human and nonhuman
primate pulmonary endotoxin challenge models, and mod-
ulate neutrophil/endothelial interactions.9 This pilot studyinvestigated the effects of GSK2862277 on measures of
lung inflammation and capillary leak in patients
undergoing oesophagectomy.
Methods
Study design and data collection
This was a multicentre, randomised placebo-controlled,
double-blind (sponsor unblind), parallel group study
(Study number TFR116341; NCT02221037).
Following screening for eligibility 7 to 28 days before
elective surgery, oesophagectomy was performed (Day 1)
under general anaesthesia with invasive positive-pressure
ventilation according to local practice. As per protocol,
ventilation during OLV procedure utilised tidal volumes
of 4 to 5 ml kg1, positive end-expiratory pressure was up
to 5 cmH2O, and SpO2 was maintained at at least 90%.
Otherwise, usual peri-operative management was fol-
lowed with fluid management or two lung ventilation
managed at the discretion of the anaesthetist. Physiolog-
ical and biochemical markers of lung injury in blood were
measured pre and postsurgery and on the following 2 to 4
days (Fig. 1), and in bronchoalveolar lavage fluid (BALF)
immediately postsurgery. Thereafter, patients were only
assessed for safety endpoints up to day 28 (as inpatients or
as outpatients if discharged before day 28).
Patients
Eligible patients were aged 18 to 80 years old undergoing
elective oesophagectomy. Full eligibility criteria are
available in the online Supplement (http://links.lww.
com/EJA/A319).
Written informed consent was obtained from all patients
before enrolment, and the study was approved by the
local ethics committee at each centre (protocol
TFR116341; NCT02221037).
Randomisation and treatment allocation
Patients were randomised to GSK2862277 or matching
placebo by means of a secure, allocation concealed,
central system. In addition patients were randomised
to one of four combinations (1 : 1 : 1 : 1) of BALF sampling
from the collapsed or ventilated lung using a randomisa-
tion schedule generated by GlaxoSmithKline (GSK)
Clinical Statistics. A pharmacist/staff nominee at each
site was unblinded to the treatment: this was necessary
for the preparation of the randomised treatment, and this
person was responsible for contacting the central alloca-
tion system to obtain the patient randomisation number.
On the morning of surgery, active or placebo preparations
were reconstituted, placed in an unmarked nebuliser cup
and handed to a member of the research team for admin-
istration as a single nebulised dose, 1 to 5 h before
oesophagectomy and before the initiation of pre-opera-
tive procedures. The investigators, who enrolled the
participants and performed the surgery, and the patientsEur J Anaesthesiol 2020; 37:1014–1024
1016 Ryan et al.










































Operating theatre ICU/surgical ward
Dosing with nebulised GSK2862277 26 mg or placebo. BAL, bronchoalveolar lavage; OLV, one-lung ventilation; OP, operation. 1On completion of
surgery, transpulmonary thermodilution measurement first then bronchoalveolar lavage were performed before tracheal extubation. 2Thermodilution
performed if patient remained in ICU with patent indwelling PiCCO catheter.themselves were blinded to study treatment but not to
the BALF sampling site. The sponsor was unblinded to
allow for instream analysis of safety data only (see further
details below under the Role of the study sponsor).
Outcome measures
Primary endpoint
The primary endpoint was the difference in the pulmo-
nary vascular permeability index (PVPI) between base-
line (immediately before surgery) and at the completion
of surgery. PVPI was calculated as the ratio of extra
vascular lung water (EVLW) to pulmonary blood volume
as described previously.18 The EVLW data were obtained
from triplicate thermodilution measurements using the
pulse contour cardiac output haemodynamic analyser
(Pulsion Medical Systems, Feldkirchen, Germany).
Secondary endpoints
Markers of lung injury
Secondary endpoint markers of lung injury were: the
difference in postoperative PVPI (days 2 to 4) from
baseline; EVLWI (EVLW indexed to the predicted body
weight); arterial partial pressure of oxygen (PaO2)/frac-
tion of inspired oxygen (FiO2) ratio at completion of
surgery and on postoperative days 2 to 4; Sequential
Organ Failure Assessment (SOFA) score on days 2 to 4.19
Safety parameters
Vital signs, ECG, routine haematology and blood chem-
istry analyses were recorded regularly during the study,
pre and postdosing and pre and postsurgery. AntibodyEur J Anaesthesiol 2020; 37:1014–1024responses to GSK2862277 were measured using a vali-
dated electrochemiluminescence (ECLIA) bridging
assay in serum samples collected predose and on Days
8 and 28 following dosing, as previously described.17
Adverse events and serious adverse events (SAEs) were
recorded throughout the study.
Pharmacodynamic and pharmacokinetic measures
Bronchoalveolar lavage (BAL) was performed after com-
pletion of surgery, but prior to tracheal extubation. For the
BAL, three successive 60 ml aliquots of 0.9% saline were
instilled into a subsegment of the middle or lingual lobe
(randomised to the collapsed or ventilated lung) and then
immediately recovered using gentle suction. The BALF
aspirated was centrifuged at 500 g for 5 min at 4 8C placed
in aliquots, and frozen at 70 8C prior to analysis.
Blood samples were processed into plasma for pharma-
cokinetic, urea and total protein analysis or serum for
pharmacodynamic [free and total soluble tumour necrosis
factor receptor 1 (sTNFR1)] and biomarker analysis.
Pharmacokinetic, free and total sTNFR1 were measured by
ECLIA (MesoScale Discovery platform, 1601 Research
Boulevard Rockville, Maryland 20850-3173), and urea
and total protein were measured using a Clinical Chemistry
analyser (Bayer Diagnostic and Pierce Bicinchoninic acid
assays, respectively), conducted by GSK. All other biomark-
ers were analysed under contract by LGC Ltd (Cambridge-
shire, UK). All assessments were made using validated
analytical methods and staff undertaking analyses were
blinded to treatment allocation.
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the online Supplement (http://links.lww.com/EJA/A319).
Statistical analysis
In this pilot study, a sample size of 80 was based on
variability and computer simulation of operating charac-
teristics derived using data from the BALTI-prevention
(The Beta Agonist Lung Injury Trial-Prevention) trial3
[with respect to PVPI and PaO2/FiO2 endpoints as
described in the protocol (see online supplement for
further details) (http://links.lww.com/EJA/A319)], and
on study feasibility.
Two interim analyses using sponsor-unblinded data were
planned for this study. The first was a safety review after
approximately 10 patients had completed Day 7 of the
study protocol, and the second was a further safety review
and a futility analysis after approximately 40 patients had
completed Day 7 of the protocol. The futility analysis was
based on joint modelling of the (baseline adjusted)
changes in PVPI and PaO2/FiO2 upon completion of
surgery, estimates of treatment effect and variability
derived from the interim data to predict the end of study
outcome and action taken according to predefined deci-
sion rules. The first interim analysis resulted in no change
to the planned study conduct; the second resulted in the
study being stopped due to futility.
For the efficacy analyses, a per protocol population,
comprising patients who received randomised treatment,
met all the inclusion/exclusion criteria and were not
classed as ‘inoperable’ once in theatre, was used. For
primary and secondary endpoints, a Bayesian statistical
framework was employed, which allows quantitative
statements to be constructed from posterior distributions
(since noninformative priors were used, the results can
also be expressed as P value equivalents). Data for PVPI
and biomarkers in BALF were log transformed before
analysis. For endpoints derived from BALF sampling, the
BAL sampling locations were pooled (via combinations of
statistical model parameters) to obtain posterior distribu-
tions of the study medication groups. Adjusted point
estimates and 95% credible intervals (Cr I) were con-
structed for each treatment, and for the comparison of
GSK2862277 with placebo using a Bayesian statistical
model that adjusts for baseline conditions and other
parameters to estimate the true treatment differences
(see online supplement for further details, http://
links.lww.com/EJA/A319). Specific posterior probabili-
ties that the true treatment difference is greater than
specified quantities were produced. A posterior probabil-
ity more than 0.975 is deemed equivalent to a statistically
significant difference between treatments at the 5% level
(P< 0.05, two-sided test). A posterior probability more
than 0.9 indicates a strong trend toward a true treatment
difference. All analyses were conducted using SAS ver-
sion 9.4., Wittington House Henley Road, Medmenham
Marlow, Buckinghamshire SL7 2EB.Plasma GSK2862277 concentration-time data were ana-
lysed by noncompartmental methods with WinNonlin
Phoenix 6.3 (Quanticate, Hertfordshire, UK).
All safety data were summarised descriptively.
Results
Study population
The study was initiated in eight secondary care centres in
the United Kingdom between April 2015 and June 2017.
Six centres screened patients and five centres enrolled
patients. After meeting the futility criteria for the second
planned interim analysis, the study was stopped after 33
patients had been enrolled and randomised to treatment.
Of those randomised, 16 received placebo and 17
GSK2862277, and 16 and 14, respectively, underwent
surgery and had available transpulmonary thermodilution
measurements (Fig. 2). For three patients randomised/
dosed with GSK2862277, curative oesophagectomy was
abandoned. Baseline characteristics and demographics
were similar for the two treatment groups (Table 1).
Primary endpoint
In contrast to previous trials in this population, there was
no change in PVPI [mean (95% Cr I)] between baseline
and completion of surgery in either group, and no differ-
ence between treatment groups: placebo 0.00 (0.23 to
0.39), GSK2862277 0.00 (0.24 to 0.37) (Fig. 3, Table 2).
Secondary endpoints
Physiological endpoints
Data for EVLWI were consistent with PVPI data in
showing minimal increase (mean change (95% Cr I) from
baseline immediately postsurgery: placebo, 0.22 ml kg1
(0.80 to 0.75); GSK2862277, 0.30 ml kg1 (2.01 to
1.65). There were also no significant changes from base-
line observed in both PVPI and EVLWI on days 2 to
4 postsurgery.
In contrast to the thermodilution assessments of lung
injury, the expected postoperative decrease in PaO2/FiO2
was apparent in placebo treated patients. However,
although the baseline adjusted mean (95% Cr I) PaO2/
FiO2 was improved in GSK2862277-treated-patients rel-
ative to placebo, 60.4 (93.2 to 116.1) and 25.4 (67.5
to 98.1) respectively, this difference was not statistically
significant and intersubject variability in PaO2/FiO2 mea-
surements was high. Finally, there were no significant
differences in organ failure SOFA scores on days 2 to 4
following surgery [Day 2 adjusted mean (95% Cr I):
placebo, 2.67 (1.78 to 3.58); GSK2862277, 3.22 (2.07 to
4.37)]. A summary of secondary physiological endpoint
results is shown in Table 2.
Safety
The frequency of adverse events was similar between treat-
ment groups [placebo 15 (94%), GSK2862277 15 (88%)
(Table S1, online Supplement, http://links.lww.com/EJA/Eur J Anaesthesiol 2020; 37:1014–1024
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Surgery performed n = 16 Surgery performed n = 14
Screening Failures, n = 16 
Did not meet inclusion/exclusion criteria: n = 14*
Investigator discretion: n=1
Study terminated: n = 1
Subjects dosed
n = 33
Randomised in error, n = 5 (none received study drug):
Surgery cancelled on day: n=3**
TB test failed: n = 1
QTC criteria failed: n = 1
Patients dosed but planned curative 
surgery abandoned (for reasons not 
related to dosing), n = 3
Primary endpoint PVPI, analysed
n = 16
Primary endpoint PVPI, analysed
n = 14
1 subject subsequently rescreened and randomised. 1 Subject subsequently randomised. PVPI, pulmonary vascular permeability index.






Age in years 60.68.3 63.39.9
Sex, n (%)
Female 2 (12) 4 (25)
Male 15 (88) 12 (75)
BMI (kg m2) 27.084.6 28.495.5
Height (cm) 173.37.5 173.48.4




17 (100) 16 (100)
Past medical conditions, n (%)
Angina 0 1 (6)
Myocardial infarction 0 1 (6)
Hyperlipidemia 2 (12) 1 (6)
Stroke 0 1 (6)
Angiodema 1 (6) 0
Polycythaemia 1 (6) 0
Cancer (breast) 0 1 (6)
Vagotomy 1 (6) 0
Parameters measured during surgery
Duration of surgery (min) 344 [305 to 399] 370 [358 to 395]
Duration of OLV (min) 140 [92 to 190] 133 [121 to 155]
Fluid balance 24 h (ml kg1) 46 [29 to 52] 40 [29 to 53]
Tidal volume (ml kg1) 6.81.8 6.21.4
PEEP (cm H2O) 5.10.6 6.43.9
Data are meanSD, median [IQR]. OLV, one-lung ventilation; PEEP, positive
end-expiratory pressure.
Eur J Anaesthesiol 2020; 37:1014–1024A319)]. Of the more commonly reported adverse events,
most were consistent with a patient’s underlying illness or
associatedwithmajorsurgery(TableS1,onlineSupplement,
http://links.lww.com/EJA/A319). Adverse events reported
by investigators as lower respiratory tract infections were
more frequent in the GSK2862277 treatment group 5 (29%)
compared with the placebo group (0). The incidence of
investigator-reported pneumonia was similar between the
placebo group 4 (25%) compared with the GSK2862277
treatment group 3 (18%). There were relatively few reports
of drug-related adverse events, but the most common was
throat irritation, reported by 4 (25%) patients in the placebo
group and none in the GSK2862277 treatment group (Table
S2, online Supplement, http://links.lww.com/EJA/A319).
There were no subject withdrawals due to an adverse event.
A post hoc review of respiratory infection events was
conducted using a standardised Medical Dictionary for
Regulatory Activities query (SMQ) to further understand
potential mechanism-related effects on respiratory tract
infections.20 SMQs are used to support signal detection
and include narrow and/or broad terms. Narrow terms are
those that are highly likely to represent the condition of
interest.20 The frequency of patients identified using the
broad terms within infective pneumonia SMQ (as defined
in the online Supplement, http://links.lww.com/EJA/
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GSK2862277 26mg IH 
Placebo GSK2862277 26mg IH 
PVPI, pulmonary vascular permeability index.





Baseline adjusted change in PVPI
On completion of surgery 0.060.503 0.080.532
Day 2 0.450.513 0.260.332
Day 3 0.310.638 0.250.516
Day 4 0.120.662 0.300.521
Baseline adjusted change in EVLWI (ml kg1)
On completion of surgery 0.1823.0249 0.0251.3357
Day 2 0.1171.3000 0.6211.8844
Day 3 0.3961.7478 0.0721.2259
Day 4 1.4242.5189 0.2843.2486
Baseline adjusted change in PaO2/FiO2
On completion of surgery 11.5181.28 0.4152.04
Day 2 29.8239.38 51.4139.74
Day 3 64.3232.83 33.7156.09
Day 4 26.5234.74 89.9101.33
Daily SOFA scores, adjusted mean (95% CI)
Day 2 3.2 (2.07 to 4.37) 2.7 (1.78 to 3.58)
Day 3 3.1 (1.80 to 4.38) 4.0 (2.30 to 5.28)
Day 4 2.9 (1.36 to 4.35) 3.1 (2.02 to 4.20)
Data are meanSD and mean (95% CI). EVLWI, extra vascular lung water index;
IH, inhaled; PaO2/FiO2, arterial partial pressure of oxygen/fraction of inspired
oxygen ratio; PVPI, pulmonary vascular permeability index; SOFA, sequential
organ failure assessment.A319) was six (38%) in placebo and nine (53%) in
GSK2862277 treated participants. Using narrow terms,
the frequency was 6 (38%) and three (18%) for placebo
and GSK2862277, respectively, with the difference
between the broad and narrow search term results being
due to the broader inclusion of chest infections (bacterial
and other causes).
The overall frequency of SAEs was eight (50%) in the
placebo group and nine (53%) in the GSK2862277 group;
the most commonly reported SAE was pneumonia [Pla-
cebo 2 (13%), GSK2862277 3 (18%)] (Table S3, online
Supplement, http://links.lww.com/EJA/A319). There
were no subject withdrawals due to a SAE.
With respect to adverse events of specific interest as
defined in the protocol, only one patient developed
ARDS (in the GSK2862277 treatment group). There
were no deaths during the study or notable differences
between treatment groups in ECGs, vital signs or labora-
tory measures. No patient tested positive for the devel-
opment of de novo antibody response to GSK2862277 over
the 28-day follow-up period.Eur J Anaesthesiol 2020; 37:1014–1024
1020 Ryan et al.Biomarkers in bronchoalveolar lavage fluid
BALF levels of free sTNFR1 were significantly reduced
[mean (95% Cr I)] in patients treated with GSK2862277:
37.66 (19.34 to 71.44) pg ml1 compared with placebo-
treated patients 231.04 (125.81 to 435.10) pg ml1, con-
firming expected binding of GSK2862277 with its target
(Fig. 4a). The Bayesian posterior probability of a reduc-
tion on GSK2862277 vs. placebo treatment was 1.00,
exceeding the predefined significance level of 0.975
(equivalent to P< 0.05).
Compared with placebo, treatment with GSK2862277
resulted in a significant reduction [mean (95% Cr I)] in
BALF levels of macrophage inflammatory protein-1 alpha
(MIP-1a) immediately postsurgery: placebo 41.86 (15.05
to 116.00) pg ml1, GSK2862277 10.88 (6.35 to






































Placebo GSK2862277 26mg IH 
(a) free soluble tumour necrosis factor receptor 1; (b) macrophage inflamma
1b; (e) IL-8; (f) IL-10; (g) IL-6; (h) TNF-a. IL, interleukin; MIP1-a, macropha
protein-1 beta; sTNFR1, soluble tumour necrosis factor receptor 1. Boxplo
box), geometric mean (solid symbol inside the box) and highest and lowes
outliers. Horizontal long dashed lines are the lower limit of quantification an
Eur J Anaesthesiol 2020; 37:1014–1024P< 0.05 (Fig. 4b). Similar but less pronounced reductions
were observed for other inflammatory biomarkers; MIP-1-
beta (b), IL-1b, IL-8, IL-10, IL-6 and TNF-a (Fig. 4c to h;
Table S4, online Supplement, http://links.lww.com/EJA/
A319).
Total protein in BALF [mean (95% Cr I)], a marker of
alveolar capillary barrier permeability, was also signifi-
cantly reduced in the lungs of patients treated with
GSK2862277: 100.24 (44.28 to 230.86) mg ml1 compared
with placebo 284.19 (140.38, 581.69) mg ml1, posterior
probability 0.977, equivalent to P< 0.05) (Fig. 5a). Simi-
lar results were observed for total protein ratio (Fig. 5b).
Nonstatistically significant reductions in markers of alve-
olar epithelial injury were observed after treatment with
GSK2862277 vs. placebo, including soluble Receptor for
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ts display the median (solid horizontal line), the interquartile range (the
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Boxplots display the median (solid horizontal line), the interquartile range (the box), geometric mean (solid symbol inside box) and highest and lowest
values (whiskers). Open symbols lying outside the whiskers denote outliers. Horizontal long dashed lines are the lower limit of quantification and
horizontal short dash lines are the upper limit of quantification.and Surfactant Protein-D (Table S5, online Supplement,
http://links.lww.com/EJA/A319). Markers of endothelial
injury in BALF could not be measured due to technical
difficulties with the assay.
GSK2862277 pharmacokinetics
From 17 patients dosed with GSK2862277, 14 had quanti-
fiable drug plasma concentrations. Following single dose
administration of GSK2862277, the geometric mean of
plasma GSK2862277 concentrations was defined in terms
of maximum plasma concentration Cmax (95% CI), 24.19
(15.12 to 38.71) ng ml1 and cumulative exposure over the
study sampling time AUC(0-t) (95% CI), 279.42 (187.38 to
416.68) ng h ml1. Absorption rate from the lungs was
relatively slow with a median time to maximum plasma
concentration (Tmax) of7.5 h. Local concentrations in the
lung were higher than those observed in plasma (Fig. 6);
however, data for lung concentrations were highly variable
(coefficient of variation between patients: 387%).
Discussion
The current pilot study was the first to assess the
effects of inhaled GSK2862277 in patients undergoing oeso-
phagectomy. Adequate exposure of the target tissue (thelungs) to GSK2862277 was achieved at pharmacologically
relevant concentrations (90% inhibitory concentration
(IC90) in BALF-derived lung epithelial lining fluid), which
was confirmed by significant target binding (reduction in
levels of free sTNFR1 due to GSK2862277 binding) both in
the lungs and in plasma. Oesophagectomy patients were
recruited into this trial as they represent a single cause with a
reproducible and timed lung injury response that, histori-
cally, has been associated with increases in transpulmonary
thermodilution-measured postoperative PVPI and EVLWI,
inflammation and a high-rate of PPCs, including ARDS.5,21
However, in contrast to previous trials in this population,3,22
minimal postoperative increases in PVPI and EVLWI were
observed in the placebo-treated patients, suggesting less
lung injury and alveolar capillary leak in patients recruited to
this trial.
Furthermore, no treatment-related differences in PVPI
and EVLWI could be discerned, either because inhibit-
ing TNFR1 signalling does not attenuate lung capillary
leak in these patients, or because the minimal increases in
PVPI and EVLWI in addition to the higher than
expected intersubject variability observed in this trial
precludes a proper assessment of efficacy against theseEur J Anaesthesiol 2020; 37:1014–1024
1022 Ryan et al.
Fig. 6. Median plasma concentrations of GSK2862277 and individual patient bronchoalveolar lavage fluid-derived lung epithelial lining fluid concentrations
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1 )endpoints. Although exploratory in nature, treatment
with GSK2862277 did not result in any significant
improvements in postoperative oxygenation (PaO2/
FiO2) or SOFA score endpoints.
The discrepant postoperative PVPI and EVLWI
increases between this and previous trials, could be
attributed to changes in anaesthetic practice, including
increased adoption of lower tidal volume ventilation
strategies and evolving fluid management over the last
7 years.23 This is partially supported by an exploratory
comparison of anaesthetic practice across BALTI-pre-
vention, VINDALOO (Vitamin D to Prevent Acute
Lung Injury Following Oesophagectomy) trials, and data
from this trial (Table S6, online Supplement, http://
links.lww.com/EJA/A319). Patient related factors, such
as cancer type, smoking and pre-operative nutrition and
changes in surgical practice may also be contributory.
Due to slower than anticipated recruitment, the second
planned interim analysis was completed after 33 patients
were enrolled instead of the planned 40 patients. After
review of data from these 33 subjects, the study was
stopped based on futility of the primary endpoint.Eur J Anaesthesiol 2020; 37:1014–1024Nebulised GSK2862277 significantly attenuated levels
of BALF protein, a biochemical marker of vascular leak
and markers of pulmonary inflammation. To ensure the
pooling of the BALF samples from collapsed and
ventilated lung for each intervention group did not
influence these results, checks were made to determine
the importance of treatment by BALF sampling loca-
tion interaction (checking size of estimate relative to
the main effect sizes) but, due to the small sample
sizes, no formal statistics methodology was employed.
However, we are confident that the BALF pooling did
not bias the data or its interpretation. The effects of
GSK2862277 on biochemical markers of lung injury
observed in this patient population are consistent with
observations in nonhuman primate and human pulmo-
nary endotoxin lipopolysaccharide challenge studies9
and confirm translation of the effects of GSK2862277
on inflammation and tissue injury to patients. Although
the clinical relevance of changes in BALF biomarkers
of inflammation and tissue injury is unclear, increased
BALF protein levels and inflammatory markers are
associated with the development of PPCs and ARDS
in surgical cohorts.24,25
Pilot study of a nebulised anti-tumour necrosis factor receptor-1 antibody 1023Treatment with GSK2862277 was generally well toler-
ated. Although a greater number of lower respiratory tract
infections were observed in the active treatment group
compared with the placebo group, when collectively
assessed post hoc by a standardised group term (infective
pneumonia SMQ), respiratory tract infections were simi-
lar between treatment groups. The incidence of postop-
erative infective pneumonia in oesophagectomy patients
is high, and in general surgical cohorts infection in the
postoperative period is strongly associated with longer
hospital stay and increased in-hospital mortality risk.26
Significantly, serial measurements of postoperative cyto-
kine levels have demonstrated a link between the mag-
nitude of the initial postoperative inflammatory response
with the extent of subsequent immunosuppression and
susceptibility to postoperative infections including
pneumonia.27 These observations raise the possibility
that attenuating the immediate peri-operative and post-
operative inflammatory response might limit the extent
of subsequent immunosuppression, and possibly also
reduce the risk of developing postoperative infections.
Conversely, further attenuation of the immune system
during the postoperative period might also potentially
worsen postoperative immunosuppression. Given these
dynamic and variable immune responses to surgical
trauma, it is important to carefully investigate the poten-
tial impact of immunotherapies such as GSK2862277
in these patients. Given the small sample size, the
effects of the short-acting, selective TNFR1 inhibitor
GSK2862277 on the incidence of postoperative infec-
tious pneumonia cannot be acertained. However, con-
sidering the established risks associated with long-
acting, nonselective anti-TNF-a therapies,28 it is
encouraging that GSK2862277 did not result in signifi-
cant increases in the incidence of postoperative pneu-
monia in the oesophagectomy patients. The results for
immunogenicity testing were also encouraging as no
patients tested positive for the formation of de novo
antibodies to GSK2862277.
The current study has some limitations. Both slow
recruitment to the study and the early termination of
the study on grounds of futility resulted in smaller than
planned patient numbers. The small number of patients
also hampered the ability to compare differences in drug
disposition and biology between hyperinflated and col-
lapsed lungs in treated patients. Finally, this study was
designed to investigate the effect of GSK2862277 on
inflammation and injury in the lungs, which was pre-
sumed to occur because of peri-operative OLV and/or
partial lung collapse. Although some systemic exposure
to GSK2862277 was anticipated and confirmed by the
reduction in free serum sTNFR1 levels on Day 1, as
expected, systemic exposure of GSK2862277 was tran-
sient and limited. Given the postoperative increase in
inflammatory biomarkers observed in the serum of
patients, it is plausible that systemic inflammation alsoprobably contributes to the development of both pul-
monary and nonpulmonary complications in oesopha-
gectomy patients. Therefore, dosing GSK2862277
systemically (e.g. intravenously), or perhaps both intra-
venously and via the inhaled route, over a longer duration
may improve the likelihood of an effect on postoperative
complications in these patients.
Conclusion
In this trial of patients undergoing oesophagectomy, pre-
operative treatment with a single 26 mg inhaled dose of
GSK2862277 did not result in significantly lower postop-
erative alveolar capillary leak or lower EVLW. Unexpect-
edly small increases in transpulmonary thermodilution-
measured PVPI and EVLWI at completion of surgery
suggest less postoperative lung injury than historically
reported in these patients, which may have also compro-
mised a clear assessment of efficacy in this trial. A single
nebulised dose of GSK2862277 was well tolerated,
resulted in the expected pharmacokinetics and lung
exposure, and reduced other biomarkers of lung perme-
ability and inflammation. The potential of GSK2862277
for future clinical use requires further exploration
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